ArticleClinical and experimental hepatology2020

SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review.

Michael Dwinata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.